Notice for concizumab (Novo Nordisk Pharmaceuticals Pty Ltd)
Active ingredients
concizumab
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Solution for subcutaneous injection
Indication
For the treatment of haemophilia B
Therapeutic area
Haematology